ASCO肺癌热点精粹

2016ASCO肺癌研究进展精粹良医汇-肿瘤资讯<br/><br/><br/>RandomizedphaseIIIstudyofadjuvantchemotherapywithorwithoutlow-molecularweightheparininpletelyresectednon-smallcelllungcancerpatients:TheNVALT-8study<br/><br/><br/>PresentedByHarryGroenat2016ASCOAnnualMeetingRationalePresentedByHarryGroenat2016ASCOAnnualMeetingHypothesisPresentedByHarryGroenat2016ASCOAnnualMeetingNVALT-8StudyDesign<br/>(afteradaptationofthedesignfromlow/highSUVmax)PresentedByHarryGroenat2016ASCOAnnualMeetingStatisticsPresentedByHarryGroenat2016ASCOAnnualMeetingObjectivePresentedByHarryGroenat2016ASCOAnnualMeetingPositronEmissionTomography<br/>useandparabilityinmultiplecentersPresentedByHarryGroenat2016ASCOAnnualMeetingIn-andexclusioncriteriaPresentedByHarryGroenat2016ASCOAnnualMeetingConsortDiagram<br/>Registeredin15hospitalsbetweenDecember2007andJuly2013PresentedByHarryGroenat2016ASCOAnnualMeetingPatientcharacteristicsPresentedByHarryGroenat2016ASCOAnnualMeetingSlide11PresentedByHarryGroenat2016ASCOAnnualMeetingAdverseeventsCTCgrade3-5<br/>PresentedByHarryGroenat2016ASCOAnnualMeetingToxicityPresentedByHarryGroenat2016ASCOAnnualMeetingRFSbytreatmentarmPresentedByHarryGroenat2016ASCOAnnualMeetingRFSstratifiedforSUVmaxriskgroupsPresentedByHarryGroenat2016ASCOAnnualMeetingConclusionsPresentedByHarryGroenat2016ASCOAnnualMeetingParticipatingCentersPresentedByHarryGroenat2016ASCOAnnualMeetingCONVERTtrial<br/>ConcurrentONce-dailyVErsustwice-dailyRadioTherapy:A2-armrandomisedcontrolledtrialofconcurrentchemo-radiotherapyparingtwice-dailyandonce-dailyradiotherapyschedulesinpatientswithlimited-stagesmallcelllungcancerandgoodperformancestatusPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingBackgroundPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingInclusioncriteriaPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingStudydesignmultinational,phaseIIIrandomisedstudyPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingStudyobjectivesPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingStatisticalassumptionsPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingRecruitmentPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingSlide8PresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingCONSORTdiagramPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingPatient<br/>characteristicsPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingTreatmentdeliveredPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingTreatmentdelivered(RT)PresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingOverallsurvivalPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingProgressionfree<br/>survivalPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingAcuteToxicityPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingAcuteToxicityPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingLateToxicityPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingSummaryPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingConclusionsPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingAcknowledgementsPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingAcknowledgements-RecruitingsitesPresentedByCorinneFaivre-Finnat2016ASCOAnnualMeetingABayesianRandomizationTrialofIntensityModulatedRadiationTherapy(IMRT)vs.<br/>3-DimensionalPassivelyScatteredProtonTherapy(3DPT)forLocallyAdvancedNon-SmallCell<br/>LungCarcinoma<br/><br/>(identifierNCT00915005)PresentedByZhongxingLiaoat2016ASCOAnnualMeetingHypothesisPresentedByZhongxingLiaoat2016ASCOAnnualMeetingRationaleforTrialDesignPresentedByZhongxingLiaoat2016ASCOAnnualMeetingPrimaryObjectivePresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide5PresentedByZhongxingLiaoat2016ASCOAnnualMeetingProtocolConsortiumDiagramPresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide7PresentedByZhongxingLiaoat2016ASCOAnnualMeetingRandomizedandTreatedAccordingtoRandomizationAnalysisPresentedByZhongxingLiaoat2016ASCOAnnualMeetingBaselineCharacteristicsPresentedByZhongxingLiaoat2016ASCOAnnualMeetingLung,EsophagusandHeart<br/>MeanDosePresentedByZhongxingLiaoat2016ASCOAnnualMeetingLungandHeartV5-V80PresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide12PresentedByZhongxingLiaoat2016ASCOAnnualMeetingRadiationPneumonitisPresentedByZhongxingLiaoat2016ASCOAnnualMeetingProtocolFailureFreeSurvival<br/>AccordingtoTimeoftheEnrollmentPresentedByZhongxingLiaoat2016ASCOAnnualMeetingOverallSurvivalPresentedByZhongxingLiaoat2016ASCOAnnualMeetingOSinNon-RandomizeblePatientsPresentedByZhongxingLiaoat2016ASCOAnnualMeetingTreatmentReceivedAnalysisinAllPatientsPresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide18PresentedByZhongxingLiaoat2016ASCOAnnualMeetingProtocolFailureFreeSurvival<br/>AccordingtoTimeoftheEnrollmentPresentedByZhongxingLiaoat2016ASCOAnnualMeetingOverallSurvival<br/>ForAllPatientsAccordingtoasTreatedPresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide21PresentedByZhongxingLiaoat2016ASCOAnnualMeetingSlide22PresentedByZhongxingLiaoat2016ASCOAnnualMeetingConclusionsPresentedByZhongxingLiaoat2016ASCOAnnualMeetingDiscussionsPresentedByZhongxingLiaoat2016ASCOAnnualMeetingAcknowledgementPresentedByZhongxingLiaoat2016ASCOAnnualMeetingTremelimumabas2nd-or3rd-linetreatmentofunresectablemalignantmesothelioma:<br/>Resultsfromtheglobal,double-blind,<br/>placebo-controlledDETERMINEstudyPresentedByHedyKindlerat2016ASCOAnnualMeetingTheUnmetNeedinMesotheliomaPresentedByHedyKindlerat2016ASCOAnnualMeetingImmuneCheckpointBlockadePresentedByHedyKindlerat2016ASCOAnnualMeetingTremelimumab:MechanismofActionPresentedByHedyKindlerat2016ASCOAnnualMeetingTremelimumabinMesotheliomaPresentedByHedyKindlerat2016ASCOAnnualMeetingDETERMINEStudyDesign<br/>Global,Randomized,Double-Blind,Placebo-Controlled,Phase2bTrialPresentedByHedyKindlerat2016ASCOAnnualMeetingKeyEligibilityCriteriaPresentedByHedyKindlerat2016ASCOAnnualMeetingDETERMINEAnalysisSetsPresentedByHedyKindlerat2016ASCOAnnualMeetingBaselineCharacteristics(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingTreatmentExposure(SafetyPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingDETERMINE:OverallSurvival(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingOSAcrossSubgroups(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingSubsequentCancerTreatment(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingInvestigator-assessedPFS(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingAntitumorActivity(ITTPopulation)PresentedByHedyKindlerat2016ASCOAnnualMeetingSafetySummaryPresentedByHedyKindlerat2016ASCOAnnualMeetingMostFrequentAEs,AnyGradePresentedByHedyKindlerat2016ASCOAnnualMeetingMostFrequentGrade≥3AEsPresentedByHedyKindlerat2016ASCOAnnualMeetingDETERMINE:Conclusions(1)PresentedByHedyKindlerat2016ASCOAnnualMeetingDETERMINE:Conclusions(2)PresentedByHedyKindlerat2016ASCOAnnualMeetingAcknowledgementsPresentedByHedyKindlerat2016ASCOAnnualMeetingSlide1PresentedByHeatherWakeleeat2016ASCOAnnualMeetingSlide2PresentedByHeatherWakeleeat2016ASCOAnnualMeetingBackground/RationalePresentedByHeatherWakeleeat2016ASCOAnnualMeetingBackground/RationalePresentedByHeatherWakeleeat2016ASCOAnnualMeetingE1505KeyEligibilityPresentedByHeatherWakeleeat2016ASCOAnnualMeetingStatisticalConsiderationsPresentedByHeatherWakeleeat2016ASCOAnnualMeetingOverviewPresentedByHeatherWakeleeat2016ASCOAnnualMeetingDemographicsoverallPresentedByHeatherWakeleeat2016ASCOAnnualMeetingDemographicsbychemotherapygroupPresentedByHeatherWakeleeat2016ASCOAnnualMeetingE1505OS+/-BevacizumabE1505DFS+/-BevacizumabPresentedByHeatherWakeleeat2016ASCOAnnualMeetingPooledChemoAnalysis(allpatientsregardlessoftreatmentarm)<br/>OSbychemogroup OSbychemogroup<br/>Non-squamous:Logrankp=0.18 Squamous:Logrankp=0.99PresentedByHeatherWakeleeat2016ASCOAnnualMeetingPooledChemoAnalysis(allpatientsregardlessoftreatmentarm)<br/>DFSbychemogroup DFSbychemogroup<br/>Non-squamous:Logrankp=0.58 Squamous:Logrankp=0.83PresentedByHeatherWakeleeat2016ASCOAnnualMeetingChemotherapyGroupparisons:Vinorelbineasreference*PresentedByHeatherWakeleeat2016ASCOAnnualMeetingSlide14PresentedByHeatherWakeleeat2016ASCOAnnualMeetingConclusions-E1505chemotherapysubsetsPresentedByHeatherWakeleeat2016ASCOAnnualMeetingAcknowledgementsPresentedByHeatherWakeleeat2016ASCOAnnualMeetingSafetyandefficacyofsingleagentrovalpituzumabtesirine(SC16LD6.5),adelta-likeprotein3(DLL3)-targetedantibody-drugconjugate(ADC)inrecurrentorrefractorysmallcelllungcancer(SCLC)PresentedByCharlesRudinat2016ASCOAnnualMeetingDisclosuresPresentedByCharlesRudinat2016ASCOAnnualMeetingSmallCellLungCancer(SCLC)PresentedByCharlesRudinat2016ASCOAnnualMeetingDelta-likeProtein3(DLL3):<br/>anoveltargetinneuroendocrinetumorsPresentedByCharlesRudinat2016ASCOAnnualMeetingRovalpituzumabTesirine(Rova-T,SC16LD6.5)PresentedByCharlesRudinat2016ASCOAnnualMeetingSCRX16-001:First-in-HumanStudySchemaPresentedByCharlesRudinat2016ASCOAnnualMeetingSubjectBaselineCharacteristics(n=74)PresentedByCharlesRudinat2016ASCOAnnualMeetingAdverseEventProfileinSCLCSubjects(n=74)PresentedByCharlesRudinat2016ASCOAnnualMeetingRECISTConfirmedResponsesperInvestigatorPresentedByCharlesRudinat2016ASCOAnnualMeetingBestResponsesperInvestigatorbyDLL3PresentedByCharlesRudinat2016ASCOAnnualMeetingCentralReviewValidatesConfirmedResponsesPresentedByCharlesRudinat2016ASCOAnnualMeetingConfirmedResponsesparablein2nd&3rdLinePresentedByCharlesRudinat2016ASCOAnnualMeetingSCLCKaplan-MeierOverallSurvivalPresentedByCharlesRudinat2016ASCOAnnualMeetingFavorableparisonvs.Existing2Land3LCTXPresentedByCharlesRudinat2016ASCOAnnualMeetingConclusions:RovalpituzumabtesirineinSCLCPresentedByCharlesRudinat2016ASCOAnnualMeetingAcknowledgementsPresentedByCharlesRudinat2016ASCOAnnualMeetingAvelumab(MSB0010718C;anti-PD-L1)inpatientswithadvancedunresectablemesotheliomafromtheJAVELINSolidTumorphase1btrial:safety,clinicalactivity,andPD-L1expressionPresentedByRaffitHassanat2016ASCOAnnualMeetingMalignantmesotheliomaPresentedByRaffitHassanat2016ASCOAnnualMeetingAvelumab*(MSB0010718C)PresentedByRaffitHassanat2016ASCOAnnualMeetingJAVELINSolidTumor:aninternational,phase1,multicohortdose-escalationanddose-expansiontrialPresentedByRaffitHassanat2016ASCOAnnualMeetingStudydesignPresentedByRaffitHassanat2016ASCOAnnualMeetingPatientsandtreatmentPresentedByRaffitHassanat2016ASCOAnnualMeetingPD-L1expressionstatusPresentedByRaffitHassanat2016ASCOAnnualMeetingTreatment-relatedAEsPresentedByRaffitHassanat2016ASCOAnnualMeetingPotentialimmune-mediatedTRAEsPresentedByRaffitHassanat2016ASCOAnnualMeetingClinicalactivityofavelumabPresentedByRaffitHassanat2016ASCOAnnualMeetingPercentchangeintargetlesionsfrombaselinePresentedByRaffitHassanat2016ASCOAnnualMeetingORRaccordingtoPD-L1expressionlevelPresentedByRaffitHassanat2016ASCOAnnualMeetingPFSbyPD-L1expressionstatusPresentedByRaffitHassanat2016ASCOAnnualMeetingResponsewithavelumab:patientcasePresentedByRaffitHassanat2016ASCOAnnualMeetingConclusionsPresentedByRaffitHassanat2016ASCOAnnualMeetingAcknowledgmentsPresentedByRaffitHassanat2016ASCOAnnualMeetingNationalCancerDataBaseAnalysisofProtonversusPhotonRadiotherapyinNon-SmallCellLungCancer(NSCLC)<br/>PresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingDisclosuresPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingBackgroundPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingBackgroundPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingBackgroundPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingSlide6PresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingProtonCentersintheUSPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingObjectivesPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingMethodsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingStatisticalMethodsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingResults-PatientCharacteristicsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingResults-PatientcharacteristicsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingProtonuseovertheyears(n=348)PresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingCharacteristicsofpatientsthatreceivedproton(n=348)PresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingCharacteristicsofpatientsthatreceivedprotonPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingPredictorsofprotontherapyPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingResults-SurvivalAnalysisPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingSurvivalAnalysisPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingSurvival-PropensityMatchedAnalysisPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingStageII/IIIPatients(n=78,621)PresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingStageII/IIIPatientsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingSurvivalAnalysis-StageII/IIIPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingSurvival-StageII/IIIPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingLimitationsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingConclusionsPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingAcknowledgementPresentedByMadhusmitaBeheraat2016ASCOAnnualMeetingLocalConsolidativeTherapy(LCT)ImprovesProgression-FreeSurvival(PFS)inPatientswithOligometastaticNon-SmallCellLungCancer(NSCLC)whodonotProgressafterFrontLineSystemicTherapy(FLST):ResultsofaMulti-InstitutionalPhaseIIRandomizedStudyPresentedByGomezat2016ASCOAnnualMeetingTrialSupportPresentedByGomezat2016ASCOAnnualMeetingIntroductionPresentedByGomezat2016ASCOAnnualMeetingTrialDesignPresentedByGomezat2016ASCOAnnualMeetingTrialDesignPresentedByGomezat2016ASCOAnnualMeetingTrialDesignPresentedByGomezat2016ASCOAnnualMeetingRandomizationPresentedByGomezat2016ASCOAnnualMeetingStatisticalConsiderationsPresentedByGomezat2016ASCOAnnualMeetingStatisticalConsiderationsPresentedByGomezat2016ASCOAnnualMeetingResultsPresentedByGomezat2016ASCOAnnualMeetingCONSORTDiagramPresentedByGomezat2016ASCOAnnualMeetingPatientCharacteristicsPresentedByGomezat2016ASCOAnnualMeetingPFSOues(updateddata)PresentedByGomezat2016ASCOAnnualMeetingPatternsofFailurePresentedByGomezat2016ASCOAnnualMeetingPatternsofFailurebyTreatmentArmPresentedByGomezat2016ASCOAnnualMeetingPatternsofFailurePresentedByGomezat2016ASCOAnnualMeetingCrossoverinNo-LCTArmPresentedByGomezat2016ASCOAnnualMeetingPrognosticFactorsforPFSPresentedByGomezat2016ASCOAnnualMeetingOverallSurvivalPresentedByGomezat2016ASCOAnnualMeetingToxicityPresentedByGomezat2016ASCOAnnualMeetingExploratoryAnalysesPresentedByGomezat2016ASCOAnnualMeetingTimetoNewSiteFailure(TNSF)PresentedByGomezat2016ASCOAnnualMeetingConclusionsPresentedByGomezat2016ASCOAnnualMeetingConclusionsPresentedByGomezat2016ASCOAnnualMeetingAcknowledgmentsPresentedByGomezat2016ASCOAnnualMeetingWeeklyPaclitaxelplusBevacizumabversusDocetaxelasSecondorThird-lineTreatmentinAdvancedNon-SquamousNon-SmallCellLungCancer(NSCLC):ResultsfromthePhaseIIIStudyIFCT-1103ULTIMATEPresentedByAlexisCortotat2016ASCOAnnualMeetingDisclosuresPresentedByAlexisCortotat2016ASCOAnnualMeetingBackgroundPresentedByAlexisCortotat2016ASCOAnnualMeetingBackgroundPresentedByAlexisCortotat2016ASCOAnnualMeetingULTIMATE:studydesignPresentedByAlexisCortotat2016ASCOAnnualMeetingEndpointsPresentedByAlexisCortotat2016ASCOAnnualMeetingKeyeligibilitycriteriaPresentedByAlexisCortotat2016ASCOAnnualMeetingStatisticaldesignPresentedByAlexisCortotat2016ASCOAnnualMeetingFlowchartPresentedByAlexisCortotat2016ASCOAnnualMeetingBaselinecharacteristicsPresentedByAlexisCortotat2016ASCOAnnualMeetingTreatmentexposurePresentedByAlexisCortotat2016ASCOAnnualMeetingTreatment-relatedAEsPresentedByAlexisCortotat2016ASCOAnnualMeetingHematologicalToxicityPresentedByAlexisCortotat2016ASCOAnnualMeetingNon-HematologicalToxicityPresentedByAlexisCortotat2016ASCOAnnualMeetingResponseRateat8weeksPresentedByAlexisCortotat2016ASCOAnnualMeetingProgression-FreeSurvivalPresentedByAlexisCortotat2016ASCOAnnualMeetingForestPlot(PFS)PresentedByAlexisCortotat2016ASCOAnnualMeetingOverallSurvivalPresentedByAlexisCortotat2016ASCOAnnualMeetingPost-discontinuationtreatmentsPresentedByAlexisCortotat2016ASCOAnnualMeetingPost-discontinuationtreatmentsPresentedByAlexisCortotat2016ASCOAnnualMeetingPost-discontinuationtreatmentsPresentedByAlexisCortotat2016ASCOAnnualMeetingQoLPresentedByAlexisCortotat2016ASCOAnnualMeetingConclusionsPresentedByAlexisCortotat2016ASCOAnnualMeetingAcknowledgementsPresentedByAlexisCortotat2016ASCOAnnualMeetingPhaseIstudy(BLOOM)ofAZD3759,aSpenetrableEGFRinhibitor,forthetreatmentofnon-small-celllungcancer(NSCLC)withbrainmetastasis(BM)andleptomeningealmetastasis(LM)PresentedByMyung-JuAhnat2016ASCOAnnualMeetingAuthordisclosurePresentedByMyung-JuAhnat2016ASCOAnnualMeetingIntroductionPresentedByMyung-JuAhnat2016ASCOAnnualMeetingBLOOMstudydesignoverviewPresentedByMyung-JuAhnat2016ASCOAnnualMeetingBLOOMstudydesign–AZD3759doseescalationPresentedByMyung-JuAhnat2016ASCOAnnualMeetingPatientdemographicsPresentedByMyung-JuAhnat2016ASCOAnnualMeetingSummaryofAEsanddoseinterruption/reductionPresentedByMyung-JuAhnat2016ASCOAnnualMeetingClinicalpharmacokineticsofAZD3759andmetabolite(AZ’1168)*PresentedByMyung-JuAhnat2016ASCOAnnualMeetingInhibitionofpEGFRexpressioninCSFtumorcellsPresentedByMyung-JuAhnat2016ASCOAnnualMeetingAnti-tumoractivityPresentedByMyung-JuAhnat2016ASCOAnnualMeetingSlide11PresentedByMyung-JuAhnat2016ASCOAnnualMeetingSlide12PresentedByMyung-JuAhnat2016ASCOAnnualMeetingIntracranialtumorshrinkageaccordingtodosePresentedByMyung-JuAhnat2016ASCOAnnualMeetingDurationoftreatmentPresentedByMyung-JuAhnat2016ASCOAnnualMeetingConclusionPresentedByMyung-JuAhnat2016ASCOAnnualMeetingBrigatinibinPatientsWithCrizotinib-RefractoryALK+Non–SmallCellLungCancer:FirstReportofEfficacyandSafetyFromaPivotalRandomizedPhase2Trial(ALTA)PresentedByDong-WanKimat2016ASCOAnnualMeetingBackgroundPresentedByDong-WanKimat2016ASCOAnnualMeetingBrigatinibExhibitsaPan-InhibitoryPreclinicalProfileAgainstALKResistanceMutantsPresentedByDong-WanKimat2016ASCOAnnualMeetingALTA:RandomizedDoseEvaluationofBrigatinibPresentedByDong-WanKimat2016ASCOAnnualMeetingKeyInclusion/ExclusionCriteriaandStudyStatusPresentedByDong-WanKimat2016ASCOAnnualMeetingDemographicsandBaselineCharacteristicsPresentedByDong-WanKimat2016ASCOAnnualMeetingObjectiveResponseRatesinCrizotinib-ResistantPatientsbyArmPresentedByDong-WanKimat2016ASCOAnnualMeetingBrigatinibAntitumorActivitybyArmPresentedByDong-WanKimat2016ASCOAnnualMeetingPFSbyArmPresentedByDong-WanKimat2016ASCOAnnualMeetingSurvivalbyArmPresentedByDong-WanKimat2016ASCOAnnualMeetingIRC-AssessedIntracranialResponseRatesPresentedByDong-WanKimat2016ASCOAnnualMeetingIntracranialPFSbyArmPresentedByDong-WanKimat2016ASCOAnnualMeeti